Video

Dr. Champlin on the Role of EASIX Following Allogeneic Stem Cell Transplant

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.

Richard E. Champlin, a professor of medicine at The University of Texas MD Anderson Cancer Center, discusses the association reported between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent allogenic stem cell transplantation (SCT).

Grade ≥2 fluid overload has been determined to be a significant adverse event with nonrelapse mortality in patients with allogenic SCT, and researchers hypothesized that endothelial damage to prior treatments before receiving allogenic SCT can be associated with this type of toxicity. In the study, predictors of ≥2 fluid overload and 6-month overall survival were evaluated, as well as EASIX scores.

Findings showed that an elevated EASIX index can identify a group of patients who are at high risk for treatment-related mortality, Champlin explains. By identifying these patients, physicians can introduce interventions that can reduce fluid and improve capillary gut syndrome. There are agents available that could reduce fluid overload appropriately in this high-risk group, he concludes.

<<< 2019 Transplantation and Cellular Therapy Meetings

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center